Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models

详细信息    查看全文

• 作者：Ana-Maria Marino^a ; ^e ; Anastasios Sofiadis^b ; ^c ; ^e ; Ninib Baryawno^d ; John Inge Johnsen^d ; Catharina Larsson^b ; ^e ; Vladana Vukojevi&#x107 ; ^a ; ^e ; Tomas J. Ekströ ; m^a ; ^e ; ^{tomas.ekstrom@ki.se"" rel=""nofollow}
• 关键词：Glioblastoma ; Medulloblastoma ; Histone deacetylase ; Receptor tyrosine kinase
• 刊名：Biochemical and Biophysical Research Communications
• 出版年：2011
• 出版时间：22 July 2011
• 年：2011
• 卷：411
• 期：1
• 页码：208-212
• 全文大小：581 K

文摘

We have investigated in vitro effects of anticancer therapy with the histone deacetylase inhibitor (HDACi) 4-phenylbutyrate (4-PB) combined with receptor tyrosine kinase inhibitors (RTKi) gefitinib or vandetanib on the survival of glioblastoma (U343MGa) and medulloblastoma (D324Med) cells. In comparison with individual effects of these drugs, combined treatment with gefitinib/4-PB or vandetanib/4-PB resulted in enhanced cell killing and reduced clonogenic survival in both cell lines. Our results suggest that combined treatment using HDACi and RTKi may beneficially affect the outcome of cancer therapy.